These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20725780)

  • 1. R-deprenyl: pharmacological spectrum of its activity.
    Magyar K; Szende B; Jenei V; Tábi T; Pálfi M; Szöko E
    Neurochem Res; 2010 Dec; 35(12):1922-32. PubMed ID: 20725780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective and neuronal rescue effects of selegiline: review.
    Magyar K; Haberle D
    Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
    Magyar K; Szende B; Lengyel J; Tekes K
    J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
    Wu RM; Chen RC; Chiueh CC
    Ann N Y Acad Sci; 2000; 899():255-61. PubMed ID: 10863544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacology of selegiline.
    Magyar K
    Int Rev Neurobiol; 2011; 100():65-84. PubMed ID: 21971003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of selegiline against selective neurotoxins].
    Magyar K
    Vopr Med Khim; 1997; 43(6):504-14. PubMed ID: 9503567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuroprotective and neuronal rescue effects of (-)-deprenyl.
    Magyar K; Szende B; Lengyel J; Tarczali J; Szatmáry I
    J Neural Transm Suppl; 1998; 52():109-23. PubMed ID: 9564614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological aspects of (-)-deprenyl.
    Magyar K; Pálfi M; Tábi T; Kalász H; Szende B; Szöko E
    Curr Med Chem; 2004 Aug; 11(15):2017-31. PubMed ID: 15279565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells].
    Jenei V; Zor K; Magyar K; Jakus J
    Orv Hetil; 2005 Mar; 146(13):601-6. PubMed ID: 15856624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline: a molecule with innovative potential.
    Tábi T; Vécsei L; Youdim MB; Riederer P; Szökő É
    J Neural Transm (Vienna); 2020 May; 127(5):831-842. PubMed ID: 31562557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl.
    Robinson JB
    Biochem Pharmacol; 1985 Dec; 34(23):4105-8. PubMed ID: 3933519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells.
    Lai CT; Yu PH
    Toxicol Appl Pharmacol; 1997 Jan; 142(1):186-91. PubMed ID: 9007048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl.
    Jenei V; Zor K; Magyar K; Jakus J
    J Neural Transm (Vienna); 2005 Nov; 112(11):1433-45. PubMed ID: 15785858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
    Tatton WG; Wadia JS; Ju WY; Chalmers-Redman RM; Tatton NA
    J Neural Transm Suppl; 1996; 48():45-59. PubMed ID: 8988461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.